Scancell Holdings
SCLP · AIM · Health Care · mcap £126m · 9.3p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 09 Oct 26 | Results | Final Results
FY26 operating loss £17.4m vs £15.0m prior year; merger with Neuphoria and $75m+ financing secured. |
−1.1% |
| 02 Oct 26 | Notice of GM
Scancell Holdings plc (AIM: SCLP) ("Scancell", or the "Company"), a late-stage clinical immuno-oncology company developing active immunotherapies designed to enhance anti-tumor immune responses in difficult-to-treat canc |
+1.6% | |
| 24 Sep 26 | Scancell completes up to US$25m in debt financing
Scancell secures up to US$25m debt facility from BlackRock to fund iSCIB1+ Phase 3 trial and Nasdaq listing. |
−1.0% | |
| 03 Sep 26 | Scancell to Present at the H.C. Wainwright Sept 26
Scancell management to present at H.C. Wainwright investment conference on September 16, 2026. |
−0.5% | |
| 19 Aug 26 | ISCIB1+ MHRA CTA Approval for Ph3 trial
MHRA approves Phase 3 clinical trial authorization for iSCIB1+ in advanced melanoma |
+1.1% | |
| 06 Aug 26 | Holding | Holding(s) in Company | |
| 31 Jul 26 | Holding | Holding(s) in Company | |
| 31 Jul 26 | Extension of Option Exercise Period
Exercise period for 3.85m CSO share options extended to 31 January 2027. |
−0.5% | |
| 28 Jul 26 | Holding | Holding(s) in Company | |
| 27 Jul 26 | Fundraise | Result of Retail Offer and Total Voting Rights
Result of Oversubscribed Retail Offer and Total Voting Rights |
+2.6% |
| 24 Jul 26 | Merger and Financing
Scancell to acquire Neuphoria in all-share merger with Nasdaq listing and up to $89m financing secured. |
−10.5% | |
| 23 Jul 26 | Fundraise | Oversubscribed UK Placing
Scancell upsized UK placing to £13.0 million after significant oversubscription, plus retail offer of up to £2.3 million. |
−17.6% |
| 23 Jul 26 | Merger and Financing
Scancell to acquire Neuphoria in all-share merger; to list on Nasdaq and raise up to $89m financing for Phase 3 trial. |
−17.6% | |
| 23 Jul 26 | Fundraise | Launch of Retail Offer
Scancell launches retail offer to raise up to £2.3m at 9p per share, conditional on UK placing completion. |
−17.6% |
| 23 Jul 26 | Fundraise | Proposed UK Placing
Proposed placing to raise approximately £9.0 million at 9 pence per share, alongside retail offer for up to £2.3 million. |
−17.6% |
| 26 Jun 26 | Response to Press Speculation
Scancell in advanced discussions with Neuphoria regarding potential reverse merger and Nasdaq listing. |
−3.2% | |
| 28 Apr 26 | FDA Fast Track Designation for iSCIB1+
FDA grants Fast Track Designation for iSCIB1+ in advanced melanoma; Phase 2 shows 77% PFS at 20 months. |
+5.8% | |
| 02 Apr 26 | Board change | CFO transition
CFO Sath Nirmalananthan leaving April 24; David Schilansky appointed interim CFO effective immediately. |
+0.0% |
| 29 Jan 26 | Results | Half-year Results
iSCIB1+ achieves 74% PFS at 16 months in Phase 2 melanoma trial; FDA clears Phase 3 IND; operating loss £8.9m. |
−2.8% |
| 26 Jan 26 | FDA clearance of IND application for iSCIB1+
FDA clears IND application for Phase 3 trial of iSCIB1+ in advanced melanoma with PFS endpoint. |
+1.3% | |
| 22 Jan 26 | Routine | Notice of Results | |
| 09 Dec 25 | Continued improvement in PFS with iSCIB1+
Phase 2 iSCIB1+ melanoma data shows 74% PFS at 16 months versus 50% standard of care. |
−4.4% | |
| 07 Nov 25 | Research Update
Phase 2 SCOPE trial shows iSCIB1+ achieved 78% PFS at 11 months versus 46% historic benchmark in melanoma. |
+1.5% | |
| 30 Oct 25 | Routine | Result of AGM |
Company filings. Not investment advice.